Despite the short-term impact of the COVID-19 pandemic, as well as barriers to patients' access to neurovascular treatments, improving healthcare infrastructure, growing demand, and clinical data supporting the endovascular approach over surgical interventions for treating neurovascular diseases will support procedure volume growth in Asia Pacific countries.

This Medtech 360 Report provides comprehensive data and analysis on the current state of the market for Neurovascular devices in Asia Pacific across a 10-year period.

The COVID-19 pandemic will impact the neurovascular device market in the short term.

How strongly will the market be affected?

Which procedures will experience the strongest impact?

How quickly will recovery occur?

The neurovascular device markets in India and China are underpenetrated compared to the Australian and South Korean markets.

What are the factors responsible for low penetration in India and China?

How will recent efforts to improve health care infrastructure in these countries affect the adoption of neurovascular devices?

What strategies will competitors use in these markets to gain revenues?

Clinical data supporting the effectiveness of neurovascular thrombectomy procedures for the treatment of ischemic stroke will fuel this market segment.

How much growth is expected in this market segment in the Asia Pacific region?

How will the uptake of these devices vary by country?

What impact have recent product launches had on the market for neurovascular thrombectomy devices?

There is high growth potential for the Asia Pacific neurovascular angioplasty device market due to the prevalence of ICAD in this region.

What factors are driving and limiting growth in neurovascular angioplasty device adoption?

What was the impact of the SAMMPRIS trial in Asia Pacific countries?

Which companies are leading the market and what has contributed to their success?

Table of contents

  • Neurovascular Devices - Market Insights - Asia Pacific

Author(s): Vandna Yadav, B.Pharm

Vandna Yadav is a research associate within Cardiovascular Medtech Insights team at DRG (Part of Clarivate), specializing in the neurovascular device market. Vandna holds a Bachelor's degree in Pharmacy from the University of Delhi and has prior experience working in market research in the health care domain for three years.